Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical Radiotherapy

Treatment decisions for men aged 70 years or over with localised prostate cancer need to take into account the risk of death from competing causes and fitness for the proposed treatment. Objective assessments such as those included in a comprehensive geriatric assessment (CGA) might help to inform the decision-making process. The aim of this study was to describe the CGA scores of a cohort of older men with prostate cancer, evaluate potential screening tools in this population and assess whether any CGA component predicts significant acute radiotherapy toxicity.

This was a prospective cohort study undertaking pretreatment CGA, Vulnerable Elders Survey (VES-13) and G8 assessment in patients aged 70 years and over with localised prostate cancer planned to undergo radical external beam radiotherapy.

In total, 178 participants were recruited over a 3 year period and underwent a CGA. Fifty-five (30.1%) participants were defined as having health needs identified by their CGA. Both VES-13 and G8 screening tools showed a statistically significant association with CGA needs (P < 0.001 and X(2) = 15.02, P < 0.001, respectively), but their sensitivity was disappointing. There was no association between a CGA (or its components) and significant acute radiotherapy toxicity.

Many older men with localised prostate cancer are vulnerable according to a CGA. The screening tools evaluated were not sufficiently sensitive to identify this group. CGA outcome does not predict for significant acute radiotherapy toxicity.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2017 Jun 04 [Epub ahead of print]

G E C Osborne, S A Appleyard, D C Gilbert, C I Jones, C Lorimer, M Villanueva, E Peasgood, A Robinson, A Nikapota, A Ring

Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK., Department of Primary Care and Public Health, Brighton and Sussex Medical School, University of Sussex, Brighton, UK., Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; Department of Medicine, Royal Marsden Hospital, Sutton, UK. Electronic address: .